This study is designed to etablish the effects of spironolactone in comparison to placebo on
the composite endpoint of nonfatal Myocardial Infarction (MI) and acute coronary syndrome,
hospitalization for heart failure, nonfatal stroke or cardiovascular-induced death. The
primary endpoint will be the time to onset of the first incident.